Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety
Mallesh Pandrala, Arne A.N. Bruyneel, Anna P. Hnatiuk, Mark Mercola, Sanjay V. Malhotra
Abstract
, that significantly inhibit the kinase activity of both native BCR-ABL and the T315I mutant. We have identified the most cardiac-safe TKIs reported to date, and they may be used to effectively treat CML patients with the T315I mutation.
Topics & Concepts
ChemistryMyeloid leukemiaLeukemiabreakpoint cluster regionCancer researchPharmacologyInternal medicineBiochemistryReceptorMedicineChronic Myeloid Leukemia TreatmentsHER2/EGFR in Cancer ResearchChronic Lymphocytic Leukemia Research